Economic evaluation finds Freestyle Libre cost-effective for patients with Type 2 Diabetes on insulin therapy in the Dutch healthcare system.
From a Dutch publicly funded healthcare system perspective, FSL can be considered to be cost-effective compared with SMBG for people living with T2DM on basal insulin therapy.
No takes yet. Share an insight, caveat, or question.
Dijk et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: